Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 3
2009 4
2010 2
2011 8
2012 4
2013 5
2014 4
2015 5
2016 4
2017 3
2018 2
2019 8
2020 8
2021 7
2022 13
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O'Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van't Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators. Garrelfs SF, et al. N Engl J Med. 2021 Apr 1;384(13):1216-1226. doi: 10.1056/NEJMoa2021712. N Engl J Med. 2021. PMID: 33789010 Clinical Trial.
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society. Herrlinger U, et al. Among authors: coch c. Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14. Lancet. 2019. PMID: 30782343 Free article. Clinical Trial.
Exosomes as nucleic acid nanocarriers.
van den Boorn JG, Dassler J, Coch C, Schlee M, Hartmann G. van den Boorn JG, et al. Among authors: coch c. Adv Drug Deliv Rev. 2013 Mar;65(3):331-5. doi: 10.1016/j.addr.2012.06.011. Epub 2012 Jun 28. Adv Drug Deliv Rev. 2013. PMID: 22750807 Review.
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.
Frishberg Y, Deschênes G, Groothoff JW, Hulton SA, Magen D, Harambat J, Van't Hoff WG, Lorch U, Milliner DS, Lieske JC, Haslett P, Garg PP, Vaishnaw AK, Talamudupula S, Lu J, Habtemariam BA, Erbe DV, McGregor TL, Cochat P; study collaborators. Frishberg Y, et al. Clin J Am Soc Nephrol. 2021 Jul;16(7):1025-1036. doi: 10.2215/CJN.14730920. Epub 2021 May 13. Clin J Am Soc Nephrol. 2021. PMID: 33985991 Free PMC article. Clinical Trial.
Targeting nucleic acid sensors in tumor cells to reprogram biogenesis and RNA cargo of extracellular vesicles for T cell-mediated cancer immunotherapy.
Heidegger S, Stritzke F, Dahl S, Daßler-Plenker J, Joachim L, Buschmann D, Fan K, Sauer CM, Ludwig N, Winter C, Enssle S, Li S, Perl M, Görgens A, Haas T, Orberg ET, Göttert S, Wölfel C, Engleitner T, Cortés-Ciriano I, Rad R, Herr W, Giebel B, Ruland J, Bassermann F, Coch C, Hartmann G, Poeck H. Heidegger S, et al. Among authors: coch c. Cell Rep Med. 2023 Sep 19;4(9):101171. doi: 10.1016/j.xcrm.2023.101171. Epub 2023 Aug 31. Cell Rep Med. 2023. PMID: 37657445 Free PMC article.
Approaching the RNA ligand for RIG-I?
Schlee M, Hartmann E, Coch C, Wimmenauer V, Janke M, Barchet W, Hartmann G. Schlee M, et al. Among authors: coch c. Immunol Rev. 2009 Jan;227(1):66-74. doi: 10.1111/j.1600-065X.2008.00724.x. Immunol Rev. 2009. PMID: 19120476 Review.
Aneurysmal Subarachnoid Hemorrhage during the Shutdown for COVID-19.
Güresir E, Gräff I, Seidel M, Bauer H, Coch C, Diepenseifen C, Dohmen C, Engels S, Hadjiathanasiou A, Heister U, Heyer I, Lampmann T, Paus S, Petzold G, Pöhlau D, Putensen C, Schneider M, Schuss P, Textor J, Velten M, Wach J, Welchowski T, Vatter H. Güresir E, et al. Among authors: coch c. J Clin Med. 2022 May 2;11(9):2555. doi: 10.3390/jcm11092555. J Clin Med. 2022. PMID: 35566681 Free PMC article.
Who is a 'healthy subject'?-consensus results on pivotal eligibility criteria for clinical trials.
Breithaupt-Groegler K, Coch C, Coenen M, Donath F, Erb-Zohar K, Francke K, Goehler K, Iovino M, Kammerer KP, Mikus G, Rengelshausen J, Sourgens H, Schinzel R, Sudhop T, Wensing G. Breithaupt-Groegler K, et al. Among authors: coch c. Eur J Clin Pharmacol. 2017 Apr;73(4):409-416. doi: 10.1007/s00228-016-2189-8. Epub 2017 Jan 7. Eur J Clin Pharmacol. 2017. PMID: 28064353 Free PMC article. Review.
72 results